Darunavir Ethanolate/Emtricitabine/Tenofovir Alafenamide Fumarate/Cobicistat

乙醇达芦那韦/恩曲他滨/富马酸磷丙替诺福韦/考比司他

Report date: 2026/03/06 20:02:51

Base Information

Drug NameDarunavir Ethanolate/Emtricitabine/Tenofovir Alafenamide Fumarate/Cobicistat
Drug Alias NameCobicistat/Darunavir/Emtricitabine/Tenofovir AlafenamideDarunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamidedarunavir, cobicistat, emtricitabine and tenofovir alafenamide fumarateSymtuza
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionCytochrome P450 3A inhibitorsReverse transcriptase inhibitorsHuman immunodeficiency virus type 1 protease inhibitors +[4] 
TargetsCytochrome P450 3AHuman immunodeficiency virus type 1 reverse transcriptaseHuman immunodeficiency virus type 1 protease +[4] 
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsHIV Infections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryGermany
Original Approved Date2017/01/01
Country/TerritoryBelgiumCanadaUnited States +[12] 
CombinationsYes Darunavir EthanolateEmtricitabineTenofovir Alafenamide Fumarate
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson Innovative Medicine
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson Innovative MedicineJanssen-Cilag International NvJanssen Products, Lp +[4] 
Inactive CompaniesJanssen Scientific Affairs LlcJanssen Sciences Ireland UcJanssen Pharmaceutical Nv
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeJ05
Related LinksN/A